Connect with us

Biotech

Sanofi boosts its consumer healthcare business in Spain with a new company

The company says the operating context of the self-care industry is different from that of the prescription drug industry. Sanofi, which will continue to own its self-care business, has made this structural move to enable self-care solutions to be made available to consumers and healthcare professionals in a more efficient manner. Sanofi has more than 1,200 employees in Spain, and two national headquarters.

Anne Kings

Published

on

Sanofi is boosting its consumer healthcare business in Spain. The French pharmaceutical company has created a new company, Opella Healthcare Spain, to increase its presence in the self-care market, sources at Sanofi have confirmed to PlantaDoce.

The French company is building, within its own organization and in different countries around the world, entities under the umbrella of Opella Healthcare. The aim of this new company is to “operate with the necessary agility and speed of the market, as well as with the maximum potential of its teams,” the sources explained.

Sanofi wants to ensure that its consumer healthcare business operates with the most advanced standards and processes applicable in this specific area, with a continued focus “on ethics, consumer safety, and quality.”

Find more about the new company founded by Sanofi in Spain and read the latest financial headlines of the day with our companion app, Born2Invest.

Sanofi seeks to apply the most advanced standards and processes in the ”er healthcare” business

The company says the operating context of the self-care industry is different from that of the prescription drug industry. Sanofi, which will continue to own its self-care business, has made this structural move to enable self-care solutions to be made available to consumers and healthcare professionals in a more efficient manner.

This same operation is being carried out by Sanofi in Argentina, Austria, Belgium, Brazil, Colombia, Czech Republic, Ecuador, Egypt, France (where these entities will be headquartered), Greece and the United Kingdom, among other countries.

Sanofi has more than 1,200 employees in Spain, two national headquarters, a center specialized in international projects, and a production plant. The French pharmaceutical company has invested $89.6 million (€74.6 million) in research, development, and innovation in the last five years.

SEE ALSO  Why you should invest in Germany's property market

Sanofi has more than 1,000 employees in Spain, where it has a specialized center and a production plant

The group has 27 molecules in clinical development in national centers, including vaccines, and last year produced 84 million units of drugs at its plant in Riells i Viabrea, in the province of Girona. Up to 120 countries receive medicines manufactured in Spain.

Sanofi Spain’s headquarters are located in Barcelona, in the Torre Diagonal Mar building. The French group’s subsidiary also has a delegation in Madrid and a sales team distributed throughout the national territory. In addition, since 2017, the company has a second headquarters in Barcelona where international corporate projects are developed.

Sanofi Spain has had its industrial center in the town of Riells i Viabrea since 1972 and is made up of a team of 300 people. The plant is one of the company’s most competitive on a global scale, with a production volume of up to 5% of the group’s worldwide manufacturing.

The plant specializes in the production of solid forms (tablets and capsules) and produces more than forty different references.

Sanofi Spain is led by Margarita López, its general manager in the country.

Sanofi tripled its profit in 2020 to $14.8 billion (€12.3 billion). The net result of Sanofi’s activities increased by 9.6% in absolute figures and by 4.2% in comparable data, to $8.83 billion (€7.35 billion). In addition, revenues rose by 3.3% to $43.3 billion (€36.04 billion).

__

(Featured image by JoaquinAranoa via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Anne Kings is a reporter for the financial sector, often tackling Wall Street and shareholders' interests. She also covers the intersection of media and technology, and delves into interesting topics on entertainment. Sometimes she also writes about the cannabis industry, in particular CBD and hemp. She is currently based in New York.